Fairmont Hotel Vancouver Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2015
Here are the related meetings in 2021:
MEETING CHANGE TO VIRTUAL: Tumor Metabolism and the Microenvironment (A4)
Tumor Metabolism and the Microenvironment (EK14)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Integrating Metabolism and Tumor Biology (J1)
Organizer(s) Ralph J. DeBerardinis, Robert T. Abraham and Eyal Gottlieb
January 13—18, 2015
Fairmont Hotel Vancouver • Vancouver, BC Canada
Discounted Abstract Deadline: Sep 24, 2014
Abstract Deadline: Oct 16, 2014
Scholarship Deadline: Sep 24, 2014
Discounted Registration Deadline: Nov 13, 2014
Sponsored by Astellas Pharma Inc., Bayer HealthCare Pharmaceuticals, Cell Signaling Technology, Inc., ImmunoGen, Inc., Pfizer Inc. and Takeda Pharmaceutical Company
Joint Meeting:
PI 3-Kinase Signaling Pathways in Disease (J2)
Summary of Meeting:
Work in recent years has demonstrated extensive interconnectivity between oncogenic signaling pathways and intermediate metabolism. Compelling evidence indicates that signaling aberrations that drive oncogenesis trigger extensive alterations in metabolic flux; conversely, mutational alterations in certain metabolic enzymes are capable of priming cells for malignancy. These observations have raised hopes that understanding the metabolic underpinnings of cellular transformation, tumor growth and metastasis will result in more effective strategies to diagnose and treat cancer. Current challenges include understanding how best to translate observations from simple models of tumor cell growth to bona fide tumors in vivo, and understanding which aspects of dysregulated cell metabolism contribute to tumor maintenance and progression. This conference will bring together scientists from academia and industry attacking this problem on many levels. A major theme of the meeting will be exploring the cross-talk between metabolism and various other dimensions of systems biology, including epigenetics, protein function, stress responses and signal transduction. Emerging principles regarding the influence of the tumor microenvironment on cellular metabolism will be discussed in detail, as will new progress toward exploiting metabolic reprogramming to image and treat cancer. The meeting is paired with one on “PI 3-Kinase Signaling Pathways in Disease,” providing a fertile environment for exchange of ideas between these two highly connected fields.
View Scholarships/Awards
Work in recent years has demonstrated extensive interconnectivity between oncogenic signaling pathways and intermediate metabolism. Compelling evidence indicates that signaling aberrations that drive oncogenesis trigger extensive alterations in metabolic flux; conversely, mutational alterations in certain metabolic enzymes are capable of priming cells for malignancy. These observations have raised hopes that understanding the metabolic underpinnings of cellular transformation, tumor growth and metastasis will result in more effective strategies to diagnose and treat cancer. Current challenges include understanding how best to translate observations from simple models of tumor cell growth to bona fide tumors in vivo, and understanding which aspects of dysregulated cell metabolism contribute to tumor maintenance and progression. This conference will bring together scientists from academia and industry attacking this problem on many levels. A major theme of the meeting will be exploring the cross-talk between metabolism and various other dimensions of systems biology, including epigenetics, protein function, stress responses and signal transduction. Emerging principles regarding the influence of the tumor microenvironment on cellular metabolism will be discussed in detail, as will new progress toward exploiting metabolic reprogramming to image and treat cancer. The meeting is paired with one on “PI 3-Kinase Signaling Pathways in Disease,” providing a fertile environment for exchange of ideas between these two highly connected fields.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
TUESDAY, JANUARY 13
WEDNESDAY, JANUARY 14
THURSDAY, JANUARY 15
FRIDAY, JANUARY 16
SATURDAY, JANUARY 17
SUNDAY, JANUARY 18
Conference Program Print | View meeting in 12 hr (am/pm) time
TUESDAY, JANUARY 13
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:00
Keynote Address (Joint)
Lewis C. Cantley,
Weill Cornell Medicine, USA
Phosphoinositide Kinases and Cancer Metabolism
Phosphoinositide Kinases and Cancer Metabolism
09:00—11:15
Oncogenic Control of Metabolism (Joint)
*
Ralph J. DeBerardinis,
University of Texas Southwestern Medical Center, USA
Emilio Hirsch,
Fondazione per la Ricerca Biomedica – ONLUS, Italy
PI3K Class II gamma Is a Rab5 Effector Selectively Controlling Endosomal Akt2 Activation Downstream Insulin Signaling
PI3K Class II gamma Is a Rab5 Effector Selectively Controlling Endosomal Akt2 Activation Downstream Insulin Signaling
John Blenis,
Weill Cornell Medical College, USA
mTOR Control of Glutamine Metabolism
mTOR Control of Glutamine Metabolism
David M. Sabatini,
Whitehead Institute for Biomedical Research, USA
mTOR and the Cell Biology of Nutrient Sensing
mTOR and the Cell Biology of Nutrient Sensing
Wei-Xing Zong,
Rutgers University, USA
Short Talk: Myc Induces Expression of Glutamine Synthetase through Thymine DNA Glycosylase-Mediated Promoter Demethylation
Short Talk: Myc Induces Expression of Glutamine Synthetase through Thymine DNA Glycosylase-Mediated Promoter Demethylation
17:00—19:00
Metabolic Perturbations that Drive Malignancy
*
Eyal Gottlieb,
Technion - Israel Institute of Technology, Israel
Matthew G. Vander Heiden,
Massachusetts Institute of Technology, USA
Role of Glycolytic Regulation in Tumor Biology
Role of Glycolytic Regulation in Tumor Biology
Julie-Aurore Losman,
Dana-Farber Cancer Institute, USA
2-Hydroxyglutarate Induces a Reversible State of Malignant Transformation
2-Hydroxyglutarate Induces a Reversible State of Malignant Transformation
Binhua (Peter) P. Zhou,
University of Kentucky College of Medicine, USA
Metabolic Facilitators of the Epithelial-Mesenchymal Transition
Metabolic Facilitators of the Epithelial-Mesenchymal Transition
17:00—19:15
PI3K Effectors
Proteins that Bind PI3K Lipid Products: Function in Cancer and Immune Disease.
*
Roger L. Williams,
Medical Research Council, UK
Alex Toker,
Beth Israel Deaconess Medical Center, USA
PI 3-Kinase and Akt at the Interface of Signaling and Metabolism
PI 3-Kinase and Akt at the Interface of Signaling and Metabolism
Yoshinori Fukui,
Medical Institute of Bioregulation, Kyushu University, Japan
Critical Roles of DOCK Family Proteins in Migration and Activation of Leukocytes
Critical Roles of DOCK Family Proteins in Migration and Activation of Leukocytes
Aaron J. Marshall,
University of Manitoba, Canada
Short Talk: Phosphatidylinositol 3,4 Bisphosphate and its Binding Protein Lammellipodin Are Required for Directional Migration of Malignant B Cells
Short Talk: Phosphatidylinositol 3,4 Bisphosphate and its Binding Protein Lammellipodin Are Required for Directional Migration of Malignant B Cells
Sonja Vermeren,
University of Edinburgh, UK
PI3K Regulates Integrin-Dependent Processes in the Neutrophil by Signaling through ARAP3
PI3K Regulates Integrin-Dependent Processes in the Neutrophil by Signaling through ARAP3
Ming O. Li,
Memorial Sloan Kettering Cancer Center, USA
Short Talk: Sestrins Function as Guanine Nucleotide Dissociation Inhibitors for Rag GTPases to Control mTORC1 Signaling
Short Talk: Sestrins Function as Guanine Nucleotide Dissociation Inhibitors for Rag GTPases to Control mTORC1 Signaling
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Mitochondrial Metabolism and Cancer
*
Marcia C. Haigis,
Harvard Medical School, USA
Ralph J. DeBerardinis,
University of Texas Southwestern Medical Center, USA
Conventional and Unconventional Roles of Mitochondrial Enzymes in Tumor Cell Metabolism
Conventional and Unconventional Roles of Mitochondrial Enzymes in Tumor Cell Metabolism
Paul Hwang,
NHLBI, National Institutes of Health, USA
Role of TP53 in Regulating Mitochondrial Metabolism
Role of TP53 in Regulating Mitochondrial Metabolism
John C. Schell,
University of Utah, USA
Short Talk: The Mitochondrial Pyruvate Carrier Enforces the Warburg Effect and Is Important for Cancer-Initiating Cell Maintenance
Short Talk: The Mitochondrial Pyruvate Carrier Enforces the Warburg Effect and Is Important for Cancer-Initiating Cell Maintenance
Pierre Sonveaux,
University of Louvain, Belgium
Short Talk: A Mitochondrial Switch Promotes Tumor Metastasis
Short Talk: A Mitochondrial Switch Promotes Tumor Metastasis
Navdeep S. Chandel,
Northwestern University, USA
Mitochondrial Metabolism Regulates Cell Proliferation and Epigenetics
Mitochondrial Metabolism Regulates Cell Proliferation and Epigenetics
Andre Catic,
Baylor College of Medicine, USA
Short Talk: Nuclear Proteolysis as a Metabolic Regulator
Short Talk: Nuclear Proteolysis as a Metabolic Regulator
Roger Geiger,
Institute for Research in Biomedicine, Switzerland
Short Talk: Influence of L-Arginine on Metabolic Networks and the Lifespan of Activated T Cells
Short Talk: Influence of L-Arginine on Metabolic Networks and the Lifespan of Activated T Cells
08:00—11:15
PI3K/Akt/mTOR in Immune Function, Inflammation
*
Bart Vanhaesebroeck,
University College London, Cancer Institute, UK
Phillip T. Hawkins,
Babraham Institute, UK
PI3K Signaling in Neutrophils
PI3K Signaling in Neutrophils
Judith A. Varner,
University of California, San Diego, USA
Short Talk: Targeting PI3Kgamma Activates Anti-Tumor Immune Responses and Promotes Cancer Survival
Short Talk: Targeting PI3Kgamma Activates Anti-Tumor Immune Responses and Promotes Cancer Survival
David A. Fruman,
University of California, Irvine, USA
Insights Concerning the Selective Action of Rapamycin in Lymphocytes
Insights Concerning the Selective Action of Rapamycin in Lymphocytes
Yina H. Huang,
Dartmouth College, USA
Short Talk: Calmodulin and PI(3,4,5)P3 Cooperatively Bind to the Itk Pleckstrin Homology Domain to Promote Efficient Calcium Signaling and IL-17A Production in T Cells
Short Talk: Calmodulin and PI(3,4,5)P3 Cooperatively Bind to the Itk Pleckstrin Homology Domain to Promote Efficient Calcium Signaling and IL-17A Production in T Cells
14:30—16:30
Workshop 1: Novel Targets and Pathways
*
Costas A. Lyssiotis,
University of Michigan, USA
Serkan Kir,
Dana-Farber Cancer Institute, USA
Tumor-Derived PTH-Related Protein Triggers Adipose Tissue Browning and Cancer Cachexia
Tumor-Derived PTH-Related Protein Triggers Adipose Tissue Browning and Cancer Cachexia
Saverio Tardito,
Beatson Institute for Cancer Research, UK
De novo Purine Biosynthesis Dictates Glutamine Dependency of Glioblastoma Cells
De novo Purine Biosynthesis Dictates Glutamine Dependency of Glioblastoma Cells
Jiyeon Kim,
University of Texas Southwestern Medical Center, USA
Unconventional Pathways of Nitrogen Metabolism in Lung Cancer
Unconventional Pathways of Nitrogen Metabolism in Lung Cancer
Jonathan L. Coloff,
University of Illinois at Chicago, USA
Regulation of Glutamine Metabolism in Epithelial Cell Proliferation and Quiescence
Regulation of Glutamine Metabolism in Epithelial Cell Proliferation and Quiescence
Atsuo T. Sasaki,
University of Cincinnati, USA
SSK1, a Novel GTP-Dependent Kinase, Detects GTP Levels and Regulates Tumorigenesis
SSK1, a Novel GTP-Dependent Kinase, Detects GTP Levels and Regulates Tumorigenesis
Etienne Audet-Walsh,
McGill University, Canada
The Estrogen-Related Receptor Gamma Is a Key Determinant of Androgens-Mediated Energy Reprogramming of Prostate Cancer Cells
The Estrogen-Related Receptor Gamma Is a Key Determinant of Androgens-Mediated Energy Reprogramming of Prostate Cancer Cells
Zhimin Lu,
University of Texas MD Anderson Cancer Center, USA
Phosphoglycerate Kinase 1 Coordinates Glycolysis and TCA Cycle in Tumorigenesis
Phosphoglycerate Kinase 1 Coordinates Glycolysis and TCA Cycle in Tumorigenesis
17:00—19:00
Model Organisms as Tools to Understand Metabolism, Growth and Cancer
*
David M. Sabatini,
Whitehead Institute for Biomedical Research, USA
Benjamin Tu,
University of Texas Southwestern Medical Center, USA
What is TORC1 doing to Cellular Metabolism?
What is TORC1 doing to Cellular Metabolism?
Alex Gould,
Francis Crick Institute, UK
Protecting Neural Stem Cells from Starvation and Hypoxia in Drosophila
Protecting Neural Stem Cells from Starvation and Hypoxia in Drosophila
Gabriela David,
Baylor College of Medicine, USA
Short Talk: Wacky Is a Novel Regulator of mTOR Signaling
Short Talk: Wacky Is a Novel Regulator of mTOR Signaling
Leonard I. Zon,
HHMI/Boston Children's Hospital, USA
The Role of Nucleotide Deficiency in the Transcriptional Regulation of Neural Crest Differentiation and Melanoma
The Role of Nucleotide Deficiency in the Transcriptional Regulation of Neural Crest Differentiation and Melanoma
17:00—19:15
PI3K in Cancer
Lori Friedman,
ORIC Pharmaceuticals, USA
Sensitivity and Resistance to PI3K Pathway Inhibitors
Sensitivity and Resistance to PI3K Pathway Inhibitors
*
Jean J. Zhao,
Dana-Farber Cancer Institute, USA
Targeting PI3K Isoforms in Cancer: Mechanistic and Therapeutic Insights from Genetic Mouse Models
Targeting PI3K Isoforms in Cancer: Mechanistic and Therapeutic Insights from Genetic Mouse Models
Inma M. Berenjeno,
University College London, Cancer Institute, UK
Short Talk: Induction of Chromosomal Instability by Oncogenic PIK3CA and its Possible Implications
Short Talk: Induction of Chromosomal Instability by Oncogenic PIK3CA and its Possible Implications
Miguel Murillo,
Institute of Cancer Research, UK
Short Talk: Disruption of the Interaction of RAS with PI3K p110alpha Induces Regression of EGFR-Driven Lung Tumors
Short Talk: Disruption of the Interaction of RAS with PI3K p110alpha Induces Regression of EGFR-Driven Lung Tumors
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Targeting Cancer Cell Metabolism
*
Michael Pollak,
Jewish General Hospital, Canada
Robert J. Gillies,
H. Lee Moffitt Cancer Center and Research Institute, USA
Buffer Therapy
Buffer Therapy
Deepak Nagrath,
University of Michigan, USA
Short Talk: Deconstructing Glutamine’s Role in Regulating Aggressiveness, Drug Sensitivity in Ovarian Cancer Cells
Short Talk: Deconstructing Glutamine’s Role in Regulating Aggressiveness, Drug Sensitivity in Ovarian Cancer Cells
Kate Yen,
Auron Therapeutics, USA
Targeting Mutant IDH in Cancer
Targeting Mutant IDH in Cancer
Reuben J. Shaw,
The Salk Institute for Biological Studies, USA
The LKB1 - AMPK Tumor Suppressor Pathway: Metabolic Reprogramming and Therapeutic Targeting
The LKB1 - AMPK Tumor Suppressor Pathway: Metabolic Reprogramming and Therapeutic Targeting
Russell G. Jones,
Van Andel Research Institute, USA
Short Talk: The Oncogenic MicroRNA miR-17-92 Regulates Tumor Metabolism through Suppression of LKB1-AMPK Signaling
Short Talk: The Oncogenic MicroRNA miR-17-92 Regulates Tumor Metabolism through Suppression of LKB1-AMPK Signaling
Gina DeNicola,
Moffitt Cancer Center, USA
Short Talk: NRF2 Regulates Serine Biosynthesis in Non-Small Cell Lung Cancer
Short Talk: NRF2 Regulates Serine Biosynthesis in Non-Small Cell Lung Cancer
Dohoon Kim,
University of Massachusetts Medical School, USA
Short Talk: SHMT2 Drives Glioma Cell Survival in the Tumor Microenvironment but Imposes a Dependence on Glycine Clearance
Short Talk: SHMT2 Drives Glioma Cell Survival in the Tumor Microenvironment but Imposes a Dependence on Glycine Clearance
08:00—11:00
PI3K/Akt/mTOR Clinical Translational - Oncology
*
Lori Friedman,
ORIC Pharmaceuticals, USA
Jerry Y. Hsu,
Genentech, Inc., USA
Clinical Development of PI3K Inhibitors at Genentech: Is There Clinical Proof of Concept with this Class of Agents in Solid Tumors?
Clinical Development of PI3K Inhibitors at Genentech: Is There Clinical Proof of Concept with this Class of Agents in Solid Tumors?
Jeffery L. Kutok,
Epizyme, Inc., USA
Short Talk: Duvelisib Inhibits Malignant B-Cell Proliferation and Disrupts Signaling from the Tumor Microenvironment through Mechanisms that are Dependent on PI3K-delta and PI3K-gamma
Short Talk: Duvelisib Inhibits Malignant B-Cell Proliferation and Disrupts Signaling from the Tumor Microenvironment through Mechanisms that are Dependent on PI3K-delta and PI3K-gamma
Arthur L. Shaffer III,
NCI, National Institutes of Health, USA
Short Talk: Mechanisms of Ibrutinib Resistance in the Aggressive, ABC-subtype of Diffuse Large B Cell Lymphoma: PI3K and Pathways to new Therapeutic Options
Short Talk: Mechanisms of Ibrutinib Resistance in the Aggressive, ABC-subtype of Diffuse Large B Cell Lymphoma: PI3K and Pathways to new Therapeutic Options
Timothy Richard Wilson,
Genentech, Inc., USA
Short Talk: Biomarker Analysis from a Phase I Dose Escalation Study of Taselisib (GDC-0032), a beta Isoform-Sparing PI3K Inhibitor
Short Talk: Biomarker Analysis from a Phase I Dose Escalation Study of Taselisib (GDC-0032), a beta Isoform-Sparing PI3K Inhibitor
Michel Maira,
Basilea Pharamceutica Int., Switzerland
PI3K Inhibitors for Cancer Treatment: Translational Research and Beyond
PI3K Inhibitors for Cancer Treatment: Translational Research and Beyond
14:30—16:30
Workshop 2: Strategies for Discovery of Therapeutic Targets and Metabolism-Targeted Drugs
*
Arkaitz Carracedo,
Center for Cooperative Research in Biosciences, Spain
Michael E. Pacold,
New York University Medical Center, USA
Selective Toxicity of a 3-Phosphoglycerate Dehydrogenase Inhibitor towards PHGDH-Dependent Cells in vitro and in vivo
Selective Toxicity of a 3-Phosphoglycerate Dehydrogenase Inhibitor towards PHGDH-Dependent Cells in vitro and in vivo
Jing Chen,
Winship Cancer Institute, Emory University, USA
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling
Robert U. Svensson,
The Salk Institute for Biological Studies, USA
Acetyl-CoA Carboxylase Inhibition by ND646 Reduces Fatty Acid Synthesis and Inhibits Tumor Growth of Human Non-Small Cell Lung Cancer Cells
Acetyl-CoA Carboxylase Inhibition by ND646 Reduces Fatty Acid Synthesis and Inhibits Tumor Growth of Human Non-Small Cell Lung Cancer Cells
Hector C. Keun,
Imperial College London, UK
MCT1-Dependent Lactate Utilisation Is an Adaptive Response that Maintains Tumor Cell Proliferation, Lipogenesis and Redox Balance under Glucose Deprivation
MCT1-Dependent Lactate Utilisation Is an Adaptive Response that Maintains Tumor Cell Proliferation, Lipogenesis and Redox Balance under Glucose Deprivation
Ayelet Erez,
Weizmann Institute of Science, Israel
Aspartate Metabolism Links the Urea Cycle with Nucleic Acid Synthesis in Cancerous Proliferation
Aspartate Metabolism Links the Urea Cycle with Nucleic Acid Synthesis in Cancerous Proliferation
Chiara Gorrini,
Campbell Family Institute for Breast Cancer Research, Canada
BRCA1-Associated Tumorigenesis: A Matter of ROS Balance
BRCA1-Associated Tumorigenesis: A Matter of ROS Balance
14:30—16:30
Workshop 1: PI3K Structure and Enzymology
*
Jonathan M. Backer,
Albert Einstein College of Medicine, USA
Takehiko Sasaki,
Tokyo Medical and Dental University, Japan
A New Methodology for Studying Phosphoinositide Signaling at the Molecular Species Level
A New Methodology for Studying Phosphoinositide Signaling at the Molecular Species Level
John E. Burke,
University of Victoria, Canada
Deciphering the Dynamic Regulation of Phosphoinositide Kinases on Membrane Surfaces
Deciphering the Dynamic Regulation of Phosphoinositide Kinases on Membrane Surfaces
Natasha S. Clayton,
University of Cambridge, UK
Regulation of PI3K Activity by Activated Cdc42-Associated Kinase (ACK)
Regulation of PI3K Activity by Activated Cdc42-Associated Kinase (ACK)
Christl Gaubitz,
University of Geneva, Switzerland
Structural basis of the Rapamycin Insensitivity of Target of Rapamycin Complex 2
Structural basis of the Rapamycin Insensitivity of Target of Rapamycin Complex 2
Goran Stjepanovic,
University of California, Berkeley, USA
Architecture and Dynamics of the Autophagic Phosphatidylinositol 3-Kinase Complex
Architecture and Dynamics of the Autophagic Phosphatidylinositol 3-Kinase Complex
Oscar Vadas,
University of Geneva, Switzerland
Regulation of PI3Kgamma Downstream of GPCRs
Regulation of PI3Kgamma Downstream of GPCRs
17:00—19:30
Metabolite Control of Gene Expression and Protein Function
*
Matthew D. Hirschey,
Duke University, USA
Craig B. Thompson,
Memorial Sloan Kettering Cancer Center, USA
Metabolic Control of Epigenetics in Cancer
Metabolic Control of Epigenetics in Cancer
Christine A. Parachoniak,
Massachusetts General Hospital Cancer Center, USA
Short Talk: Mutant IDH Blocks Murine Primary Liver Progenitor Cell Differentiation to Drive Liver Cancer Pathogenesis
Short Talk: Mutant IDH Blocks Murine Primary Liver Progenitor Cell Differentiation to Drive Liver Cancer Pathogenesis
Eric M. Verdin,
Buck Institute for Research on Aging, USA
Mitochondrial Protein Acylation and the Sirtuins
Mitochondrial Protein Acylation and the Sirtuins
Marcia C. Haigis,
Harvard Medical School, USA
Post-Translational Modifications and Control of Mitochondrial Metabolism
Post-Translational Modifications and Control of Mitochondrial Metabolism
Poul H. B. Sorensen,
University of British Columbia, Canada
The eEF2K Translation Factor and Metabolic Reprogramming in Tumor Cells
The eEF2K Translation Factor and Metabolic Reprogramming in Tumor Cells
17:00—19:15
PI3K/Akt/mTOR Clinical Translational - Inflammation
*
David A. Fruman,
University of California, Irvine, USA
Stephen Shuttleworth,
Karus Therapeutics, UK
Design and Development of New Class of PI3K-p110beta/delta Inhibitors for the Treatment of Immune-Inflammatory Disease
Design and Development of New Class of PI3K-p110beta/delta Inhibitors for the Treatment of Immune-Inflammatory Disease
Augustin Amour,
GlaxoSmithKline, UK
The Development of a Promising Inhaled PI3Kdelta Inhibitor for the Treatment of Respiratory Indications
The Development of a Promising Inhaled PI3Kdelta Inhibitor for the Treatment of Respiratory Indications
Alison Mary Condliffe,
University of Sheffield, UK
Activated PI3 Kinase Delta Syndrome (APDS): A Novel Combined Immunodeficiency Disorder
Activated PI3 Kinase Delta Syndrome (APDS): A Novel Combined Immunodeficiency Disorder
Carrie L. Lucas,
Yale University, USA
Short Talk: Lymphoproliferation and CD8 T Cell Senescence in Primary Human Immunodeficiencies caused by Gene Mutations that Activate PI3K Signaling
Short Talk: Lymphoproliferation and CD8 T Cell Senescence in Primary Human Immunodeficiencies caused by Gene Mutations that Activate PI3K Signaling
Yan-xia Ye,
Peking Union Medical College Hospital, China
Short Talk: Defective PTEN Regulation and Function Contributes to B Cell Hyper-Responsiveness in Systemic Lupus Erythematosus
Short Talk: Defective PTEN Regulation and Function Contributes to B Cell Hyper-Responsiveness in Systemic Lupus Erythematosus
08:00—11:15
Metabolic Consequences of Cell Stress
*
Robert T. Abraham,
Vividion Therapeutics, USA
Eileen P. White,
Rutgers University, USA
Autophagy, Metabolism and Cancer
Autophagy, Metabolism and Cancer
Eyal Gottlieb,
Technion - Israel Institute of Technology, Israel
Pyruvate Carboxylation Is Required for Growth of Succinate Dehydrogenase-Deficient Cells
Pyruvate Carboxylation Is Required for Growth of Succinate Dehydrogenase-Deficient Cells
Karen H. Vousden,
Francis Crick Institute, UK
A Role for p53 in the Regulation of Metabolism
A Role for p53 in the Regulation of Metabolism
Kun-Liang Guan,
University of California, San Diego, USA
The Hippo-YAP Pathway in Organ Size Control and Tumorigenesis
The Hippo-YAP Pathway in Organ Size Control and Tumorigenesis
Andrew M. Intlekofer,
Memorial Sloan Kettering Cancer Center, USA
Short Talk: L-2-Hydroxyglutarate Production in Response to Hypoxic Stress
Short Talk: L-2-Hydroxyglutarate Production in Response to Hypoxic Stress
Bo Li,
Sun Yat-sen University, China
Short Talk: Fructose-1,6-Bisphosphatase Opposes Renal Carcinoma Progression
Short Talk: Fructose-1,6-Bisphosphatase Opposes Renal Carcinoma Progression
08:00—11:15
Class II/III PI3K, Trafficking
Linking Vps34 Regulation of Trafficking with Other Sessions - Autophagy, Metabolism.
*
Phillip T. Hawkins,
Babraham Institute, UK
Bart Vanhaesebroeck,
University College London, Cancer Institute, UK
New Physiological Roles of PI3K Isoforms
New Physiological Roles of PI3K Isoforms
Volker Haucke,
Leibniz Forschungsinstitut für Molekulare Pharmakologie, Germany
Spatiotemporal control of endocytosis and endosomal membrane traffic by PI 3-phosphates
Spatiotemporal control of endocytosis and endosomal membrane traffic by PI 3-phosphates
Nadia L. Jaber,
Stony Brook University, USA
Short Talk: Vps34 Controls Rab7 to Regulate Endocytic Trafficking
Short Talk: Vps34 Controls Rab7 to Regulate Endocytic Trafficking
Sharon A. Tooze,
Francis Crick Institute, UK
The Role of PI3P and WIPI2 in Autophagy
The Role of PI3P and WIPI2 in Autophagy
Gilbert Di Paolo,
Denali Therapeutics Inc., USA
Dysregulation of Class III PI3K/Vps34 Signaling in Neurons Recapitulates Key Features of Alzheimer's Disease
Dysregulation of Class III PI3K/Vps34 Signaling in Neurons Recapitulates Key Features of Alzheimer's Disease
Svetlana A. Fayngerts,
Adaptimmune LLC, USA
Short Talk: Of Cell Life and Death: The Phosphoinositide Transfer Domain of the TNFAIP8 Family
Short Talk: Of Cell Life and Death: The Phosphoinositide Transfer Domain of the TNFAIP8 Family
14:30—16:30
Joint Workshop: Autophagy and Regulation of Anabolic/Catabolic Balance (Joint)
*
Leon O. Murphy,
Casma Therapeutics, USA
*
Daniel J. Murphy,
University of Glasgow, UK
Rushika M. Perera,
University of California, San Francisco, USA
Transcriptional Control of the Autophagy-Lysosome System Drives Amino Acid Metabolism in Pancreatic Cancer
Transcriptional Control of the Autophagy-Lysosome System Drives Amino Acid Metabolism in Pancreatic Cancer
Assia Shisheva,
Wayne State University School of Medicine, USA
Class III PI 3-Kinase Is the Main Source of PtdIns3P Substrate and Membrane Recruitment Signal for PIKfyve Constitutive Function in Endomembrane Homeostasis
Class III PI 3-Kinase Is the Main Source of PtdIns3P Substrate and Membrane Recruitment Signal for PIKfyve Constitutive Function in Endomembrane Homeostasis
Aimee L. Edinger,
University of California, Irvine, USA
Sphingolipid Drugs that Starve Cancer Cells from Inside and Out
Sphingolipid Drugs that Starve Cancer Cells from Inside and Out
Masayuki Noguchi,
Hokkaido University, Japan
The Links between AKT and Two Intracellular Proteolytic Cascades: Ubiquitination and Autophagy
The Links between AKT and Two Intracellular Proteolytic Cascades: Ubiquitination and Autophagy
Julien Planchais,
INSERM U1016, CNRS UMR 8104, Institut Cochin, Université Paris Descartes, France
The Glucose-Responsive Transcription Factor ChREBP Enhances Glucose-Dependent Anabolic Biosynthesis and Hepatocyte Proliferation in a PI3K/Akt Dependent Manner
The Glucose-Responsive Transcription Factor ChREBP Enhances Glucose-Dependent Anabolic Biosynthesis and Hepatocyte Proliferation in a PI3K/Akt Dependent Manner
Michael Pollak,
Jewish General Hospital, Canada
Serine Deprivation Enhances Anti-Neoplastic Activity of Biguanides
Serine Deprivation Enhances Anti-Neoplastic Activity of Biguanides
Biplab Dasgupta,
Cincinnati Children's Hospital, USA
AMP Kinase: Evolving Lessons about its Context-Dependent Opposite Roles in Cancer
AMP Kinase: Evolving Lessons about its Context-Dependent Opposite Roles in Cancer
17:00—18:45
Influence of the Metabolic Environment on Cancer Development and Tumor Growth
*
Matthew G. Vander Heiden,
Massachusetts Institute of Technology, USA
Dafna Bar-Sagi,
New York University School of Medicine, USA
Oncogenic Ras-Mediated Metabolic Adaptation
Oncogenic Ras-Mediated Metabolic Adaptation
Philipp E. Scherer,
University of Texas Southwestern Medical Center, USA
Adipokines and Tumor Progression
Adipokines and Tumor Progression
Robert T. Abraham,
Vividion Therapeutics, USA
Glutamine Deprivation Stimulates a Stress-Response Network in Cancer Cells
Glutamine Deprivation Stimulates a Stress-Response Network in Cancer Cells
17:00—18:45
PI3K Structure and Regulation
Insights into Structure of PI3K Enzymes, Inhibitor Binding, and Other Modes of Regulation.
*
John E. Burke,
University of Victoria, Canada
Leon O. Murphy,
Casma Therapeutics, USA
Generation of Selective VPS34 Inhibitors to Probe the Autophagy Pathway
Generation of Selective VPS34 Inhibitors to Probe the Autophagy Pathway
Jonathan M. Backer,
Albert Einstein College of Medicine, USA
The Complex Functions of p110beta: A Critical Integrator of Signals from GPCRs and Small GTPases.
The Complex Functions of p110beta: A Critical Integrator of Signals from GPCRs and Small GTPases.
19:15—20:15
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
|
|
|
|
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
|
|
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
